193 related articles for article (PubMed ID: 33242376)
1. Down Syndrome-Associated Arthritis Cohort in the New Childhood Arthritis and Rheumatology Research Alliance Registry: Clinical Characteristics, Treatment, and Outcomes.
Jones JT; Smith C; Becker ML; Lovell D;
Arthritis Care Res (Hoboken); 2021 Dec; 73(12):1739-1745. PubMed ID: 33242376
[TBL] [Abstract][Full Text] [Related]
2. A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry.
Batthish M; Berard R; Cabral D; Bolaria R; Chédeville G; Duffy C; Gerhold K; Gerschman T; Huber A; Proulx-Gauthier JP; Rosenberg A; Rumsey D; Schmeling H; Shiff N; Soon G; Bruns A; Tucker L; Guzman J;
Rheumatology (Oxford); 2020 Oct; 59(10):2796-2805. PubMed ID: 32044978
[TBL] [Abstract][Full Text] [Related]
3. Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Mannion ML; Xie F; Horton DB; Ringold S; Correll CK; Dennos A; Beukelman T;
J Rheumatol; 2021 Aug; 48(8):1322-1329. PubMed ID: 32934124
[TBL] [Abstract][Full Text] [Related]
4. Assessment and treatment of Down syndrome-associated arthritis: a survey of pediatric rheumatologists.
Nicek A; Talib N; Lovell D; Smith C; Becker ML; Jones JT
Pediatr Rheumatol Online J; 2020 Jul; 18(1):57. PubMed ID: 32660497
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
[TBL] [Abstract][Full Text] [Related]
6. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.
Ong MS; Ringold S; Kimura Y; Schanberg LE; Tomlinson GA; Natter MD;
Arthritis Rheumatol; 2021 Oct; 73(10):1910-1920. PubMed ID: 34105303
[TBL] [Abstract][Full Text] [Related]
7. The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months.
Beukelman T; Kimura Y; Ilowite NT; Mieszkalski K; Natter MD; Burrell G; Best B; Jones J; Schanberg LE;
Pediatr Rheumatol Online J; 2017 Apr; 15(1):30. PubMed ID: 28416023
[TBL] [Abstract][Full Text] [Related]
8. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
Beukelman T; Ringold S; Davis TE; DeWitt EM; Pelajo CF; Weiss PF; Kimura Y;
J Rheumatol; 2012 Sep; 39(9):1867-74. PubMed ID: 22859354
[TBL] [Abstract][Full Text] [Related]
9. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
[TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
11. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.
Kimura Y; Grevich S; Beukelman T; Morgan E; Nigrovic PA; Mieszkalski K; Graham TB; Ibarra M; Ilowite N; Klein-Gitelman M; Onel K; Prahalad S; Punaro M; Ringold S; Toib D; Van Mater H; Weiss JE; Weiss PF; Schanberg LE;
Pediatr Rheumatol Online J; 2017 Apr; 15(1):23. PubMed ID: 28399931
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
15. Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis.
Buckley L; Ware E; Kreher G; Wiater L; Mehta J; Burnham JM
J Rheumatol; 2020 Feb; 47(2):273-281. PubMed ID: 31308202
[TBL] [Abstract][Full Text] [Related]
16. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].
Niewerth M; Minden K; Klotsche J; Horneff G
Z Rheumatol; 2014 Aug; 73(6):532-40. PubMed ID: 25096586
[TBL] [Abstract][Full Text] [Related]
18. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
[TBL] [Abstract][Full Text] [Related]
19. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis.
Ringold S; Weiss PF; Colbert RA; DeWitt EM; Lee T; Onel K; Prahalad S; Schneider R; Shenoi S; Vehe RK; Kimura Y;
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1063-72. PubMed ID: 24339215
[TBL] [Abstract][Full Text] [Related]
20. Clinical Features and Treatment of Down Syndrome Arthropathy: Experience from Two US Tertiary Hospitals.
Jones JT; Talib N; Lovell D; Becker ML
Paediatr Drugs; 2019 Feb; 21(1):33-39. PubMed ID: 30547384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
